Delcath Systems Appoints Bridget Martell to Board of Directors

Delcath Systems, Inc., an interventional oncology company listed on Nasdaq (DCTH), focuses on treating primary and metastatic liver cancers. The company has recently announced the appointment of Dr. Bridget Martell to its Board of Directors, effective May 23, 2024. John Sylvester, Chairman of Delcath’s Board, expressed enthusiasm about Dr. Martell’s addition, highlighting her vast experience in senior management and directorship roles across various biotechnology firms and her expertise in oncology clinical development.

Dr. Martell currently holds independent director positions at publicly traded companies Aligos Therapeutics (Nasdaq: ALGS) and Achieve Life Sciences (Nasdaq: ACHV). She previously served on the board of POINT Biopharma Global, Inc. (Nasdaq: PNT) from June 2023 until its acquisition by Eli Lilly in December 2023, as well as Ayala Pharmaceuticals until its assets were acquired by Immunome in March 2024. Recently, Dr. Martell joined Two Bear Capital as a Biotechnology Operating Partner. Before this, she founded and managed BAM Consultants, a consultancy focused on biotechnology. During her tenure, she held executive roles such as President and CEO of Artizan Biosciences, Inc. and served as Chief Medical Officer for various biotechnology companies at different stages of development.

Dr. Martell’s educational background includes a B.S. in microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from Chicago Medical School. She completed her internship and residency in internal medicine, serving as an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Board certified in both Internal and Addiction Medicine, Dr. Martell was also a Teaching Attending and Clinical Associate Professor at Yale from 2005 to 2020. She continues to be engaged with Yale as an Entrepreneur In Residence at Yale Ventures since 2017.

On her appointment, Dr. Martell expressed her excitement about joining Delcath’s Board, particularly during this pivotal time in the company’s growth. She looks forward to aiding in both Delcath’s immediate commercial objectives and its long-term clinical development strategy.

Delcath Systems, Inc. specializes in the treatment of liver cancers through its proprietary products, HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery Systems. The HEPZATO KIT combines the chemotherapeutic agent melphalan with Delcath’s Hepatic Delivery System (HDS), intended for high-dose chemotherapy delivery to the liver while managing systemic exposure and side effects. In the U.S., this kit is a combination drug-device product regulated by the FDA and is approved for use in treating adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases, provided certain conditions are met regarding the extent of liver and extrahepatic disease.

In Europe, the device-only version of the HDS is classified as a Class III medical device and is marketed under the name CHEMOSAT Hepatic Delivery System for Melphalan. This system has been utilized in percutaneous hepatic perfusion (PHP) procedures at prominent medical centers to treat various liver cancers, making it a critical asset in Delcath’s arsenal against liver malignancies.